HS-10517 + ritonavir

HS-10517 + ritonavir is a combination drug consisting of the investigational agent **HS-10517** and the approved antiretroviral **ritonavir**. Ritonavir is a **small molecule HIV-1 protease inhibitor** primarily used as a pharmacokinetic enhancer (or "booster") because it potently inhibits cytochrome P450 3A4 (CYP3A4), thereby increasing the bioavailability and plasma concentration of co-administered drugs[2][3][1]. Ritonavir enables improved pharmacokinetics for many antiviral agents and is commonly used with various HIV and hepatitis C antivirals, as well as COVID-19 treatments. No concrete information about HS-10517 (structure, class, mechanism, developer, or indications) is available from current sources; it is likely a novel investigational compound under evaluation in combination with ritonavir, possibly as a boosted antiviral therapy. The mechanism of action for ritonavir is to inhibit HIV-1 protease enzyme, preventing HIV replication[3]. Ritonavir as a booster works by inhibiting drug metabolism through CYP3A4 blockade[2].

Brand names

HS-10517 + ritonavir

Other names

HS-10517 + ritonavir